SINT SINTX TECHNOLOGIES INC.

SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Salt Lake City, Utah, Feb. 26, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc., (“SINTX” or the “Company”) (Nasdaq: SINT), a leader in advanced ceramics for medical applications, today announced that it has, pursuant to a securities purchase agreement with institutional and accredited investors dated February 20, 2025, issued and sold 1,449,287 shares of common stock (or pre-funded warrants in lieu therof) at a purchase price of $3.45 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors in the offering unregistered warrants (the “warrants”) to purchase up to an aggregate of 1,449,287 shares of common stock. The warrants are exercisable immediately at an exercise price of $3.32 per share and will expire five and one-half years from the date of issuance. The offering closed on February 25, 2025.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the private placement were approximately $5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital purposes.

The shares of common stock, pre-funded warrants and warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the pre-funded warrants, the warrants and the shares of common stock underlying the pre-funded warrants and warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SINTX Technologies, Inc.

Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets.

For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the anticipated use of proceeds from offering. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulties in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expa...

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX T...

 PRESS RELEASE

SINTX Technologies to Participate in Noble Capital Markets’ Emerging G...

SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period o...

 PRESS RELEASE

SINTX Technologies to Participate in Sidoti & Company Investor Confere...

SINTX Technologies to Participate in Sidoti & Company Investor Conference SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic ...

 PRESS RELEASE

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复...

SINTX Technologies 与 EVONIK 签署供应协议,将生产用于人工智能辅助 3D 打印患者定制植入物的氮化硅-PEEK 复合材料 该里程碑使 SiN/PEEK 定制器械能够立即投产 犹他州盐湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先进陶瓷和生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (简称“SINTX”或“公司”)今天宣布,已与高性能聚合物领域的全球领导企业 Evonik Corporation(简称“EVONIK”)签署供应协议,由 EVONIK 生产 SINTX 的专有氮化硅-PEEK 复合材料(SiN/PEEK,美国专利号 10806831)。该材料专为人工智能辅助的患者定制植入物增材制造而设计,并将使用 SINTX 位于美国的现有生产设施完成制造。 根据协议,EVONIK 将利用其商业规模生产能力,按照 SINTX 的规格生产 SiN/PEEK 复合材料,使 SINTX 能够立即开始制造人工智能设计 3D 打印患者定制植入物。 SINTX 公司已经收到医生提出的请求,希望该公司能为脊柱肿瘤切除术后的骨科和神经外科肿瘤患者提供用于人道主义用途的椎体置换 (VBR) 植入物。 此外,该公司计划使用 SiN/PEEK 复合材料支持患者匹配型植入物及采用传统减材制...

 PRESS RELEASE

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合...

SINTX Technologies 與 EVONIK 簽署供應協議,生產用於人工智能輔助 3D 打印患者專屬植入物的氮化矽–PEEK 複合材料 此里程碑讓 SiN/PEEK 定制儀器得以即時投產 猶他州鹽湖城, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先進陶瓷與生物材料公司 SINTX Technologies, Inc. (NASDAQ: SINT) (「SINTX」或「該公司」) 今日宣佈,已與高性能聚合物全球領導者 Evonik Corporation (「EVONIK」) 簽署供應協議,生產該公司專利的氮化矽–PEEK(即聚醚醚酮)複合材料 (SiN/PEEK) (美國專利編號:10,806,831),此材料專為人工智能 (AI) 輔助增材製造患者專屬植入物而設計,將運用 SINTX 美國生產基地現有設備來生產。 根據協議,EVONIK 將發揮達到商業規模的生產能力,按照 SINTX 規格生產 SiN/PEEK 複合材料,使該公司能夠立即開始製造由 AI 設計、3D 打印的患者專屬植入物。SINTX 已收到醫生請求,為脊椎腫瘤切除後的骨科及神經外科腫瘤患者,提供人道使用的椎體替換(VBR)植入式儀器。此外,該公司打算運用 SiN/PEEK 複合材料,支援患者匹配及傳統減材製造植入式儀器的監管批准。 SINTX 主席、董事長暨行...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch